Medicine and Dentistry
Vesiculovirus
100%
Pancreas Cancer
100%
Oncolytic Virus
100%
Adenocarcinoma
75%
Ruxolitinib
41%
Protein P53
16%
Oncolytic Virotherapy
16%
Antivirus Agent
16%
Neoplasm
16%
Cell Line
8%
Cancer
8%
Virus Replication
8%
Immune Response
8%
Clinical Trial
8%
Chemotherapy
8%
Disease
8%
Viral Replication
8%
Biological Marker
8%
Drug Resistance
8%
Immunotherapy
8%
Janus Kinase 2 Inhibitor
8%
Malignant Neoplasm
8%
Adenocarcinoma Cell Line
8%
Pancreatic Ductal Adenocarcinoma
8%
Cancer Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Oncolytic Virus
100%
Vesiculovirus
100%
Adenocarcinoma
83%
Ruxolitinib
41%
Virotherapy
16%
Malignant Neoplasm
16%
Neoplasm
16%
Chemotherapy
16%
Antivirus Agent
16%
Protein P53
16%
Drug Resistance
8%
Biological Marker
8%
Immunotherapy
8%
Clinical Trial
8%
Disease
8%
Janus Kinase 2 Inhibitor
8%
Keyphrases
Vesicular Stomatitis Virus
50%
Pancreatic Cancer
50%
Oncolytic Virus
50%
Ductal Adenocarcinoma
45%
Ruxolitinib
18%
Anti-PD-1 Antibody
18%
Virus
13%
JAK-STAT
9%
Oncolytic Vesicular Stomatitis Virus
9%
Tumor
9%
Antiviral Activity
9%
Jakafi
9%
Chemotherapy Toxicity
9%
Virus Replication
9%
Treatment Survival
9%
Acquired Chemoresistance
9%
JAK2 Inhibitor
9%
Non-malignant Cells
9%
Antibody Combinations
9%
Adenocarcinoma Cells
9%